CureVac N.V. (5CV.DE)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
3.42
-0.08 (-2.40%)
At close: Feb 14, 2025, 5:29 PM
undefined% (undefined)
Bid | n/a |
Market Cap | 766.68M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.47 |
PE Ratio (ttm) | 7.27 |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 68,350 |
Avg. Volume (20D) | 140,880 |
Open | 3.63 |
Previous Close | 3.50 |
Day's Range | 3.40 - 3.63 |
52-Week Range | 2.11 - 4.81 |
Beta | undefined |
About 5CV.DE
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 25, 2020
Employees 999
Stock Exchange XETRA
Ticker Symbol 5CV.DE
Website https://www.curevac.com